Welcome to Arctom, sign up to enjoy up to 20% OFF

Search in Small Molecules Search in Biologics

Structure Search

Cart - 0 item(s)
$0.00

Your shopping cart is empty!

Chemistry
Inhibitors
- Anti-infection
Natural Products
ADCs
Antibodies
Multiplex IHC
Material Science
Others

[CAS NO. 88040-23-7] Cefepime

Ships within

Stock

Price

Qty

Total

COA

Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.

Catalog:	HY-B0692
Brand:	MCE
CAS:	88040-23-7

Overview

MDL	-
Molecular Weight	480.56
Molecular Formula	C19H24N6O5S2
SMILES	C[N+]1(CC(CS[C@]2([H])[C@@H]3NC(/C(C4=CSC(N)=N4)=N\OC)=O)=C(C([O-])=O)N2C3=O)CCCC1

For research use only. We do not sell to patients.

2 Publications Citing Use of MCE

[1]J Antibiot (Tokyo). 2023 Feb 1.
[2]Animal Diseases. 02 November 2021.

Summary

Cefepime (BMY-28142) is a broad-spectrum and cross the blood-brain barrier cephalosporin. Cefepime shows antibacterial effects against both Gram-positive and Gram-negative aerobic bacteria. Cefepime induces neurotoxicity ^[1] ^[2] ^[3] ^[4] .

IC50 & Target

Gram-positive and Gram-negative aerobic bacteria ^[1]

In Vitro

Cefepime chloride exerts its antibacterial effects by binding to penicillin-binding proteins ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Cefepime (80 mg/kg; i.p.) significantly increases the half-life and mice surviveed ^[4] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male CD-1 mice ^[4]
Dosage:	80 mg/kg
Administration:	I.p.
Result:	Significantly prolonged the half-life of cefepime and all mice survived at 18-22 mg/kg cisplatin, and when pretreatment with 26 mg/kg cisplatin significantly decreased survival with the half-life of cefepime was not significantly longer than of 18 mg/kg cisplatin.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT02680600	Onze Lieve Vrouw Hospital\|University Ghent	Antimicrobial Treatment	March 2014	Not Applicable
NCT02820987	Centre Hospitalier Universitaire de Besancon	Septic Shock	September 1, 2016	Phase 3
NCT02497781	Pfizer\|PRA Health Sciences	Complicated Urinary Tract Infections	September 24, 2015	Phase 2
NCT03685084	Allecra	Healthy	October 10, 2013	Phase 1
NCT00137787	Center for Supporting Hematology-Oncology Trials\|Bayer	Febrile Neutropenia	April 2005	Phase 3
NCT01667094	The Alfred	Cystic Fibrosis	September 2012	Phase 4
NCT01110408	Janssen Research & Development, LLC	Complicated Urinary Tract Infections or Pyelonephritis	December 2010	Phase 3
NCT02532140	Wockhardt\|Quintiles, Inc.	Healthy	August 2015	Phase 1
NCT04187755	Indonesia University	Neutropenia, Febrile\|Leukemia\|Pediatric Cancer\|Antibiotic Reaction	March 1, 2019	Phase 4
NCT00358202	CPL Associates\|Elan Pharmaceuticals	Pneumonia	March 2002	Phase 4
NCT05079620	UConn Health	Aspiration\|Aspiration Pneumonia	November 30, 2021	Phase 4
NCT03078010	Memorial Sloan Kettering Cancer Center	Intestinal Microbiome\|Febrile Neutropenia	February 10, 2017	Phase 2
NCT04233996	Hospital Universitari de Bellvitge\|Institut d´Investigació Biomèdica de Bellvitge\|Instituto de Salud Carlos III	Febrile Neutropenia	June 5, 2019	Phase 4
NCT02568800	Hospital de Clinicas de Porto Alegre	Urinary Tract Infection\|Respiratory Tract Infection	October 2015	Phase 3
NCT01852630	Institute of Liver and Biliary Sciences, India	Spontaneous Bacterial Peritonitis	December 2012	Not Applicable
NCT04948463	Murdoch Childrens Research Institute	Febrile Neutropenia	November 15, 2021	Phase 4
NCT02709382	Wockhardt\|Clinartis	Renal Impairment	March 2016	Phase 1
NCT00529282	Basilea Pharmaceutica	Fever\|Neutropenia\|Gram-positive Bacterial Infections\|Pseudomonas Infection	October 2007	Phase 3
NCT01110421	Janssen Research & Development, LLC	Pneumonia, Bacterial\|Community-Acquired Infections\|Nosocomial Infection\|Pneumonia, Ventilator-Associated	December 2010	Phase 3
NCT00497744	Hospital Authority, Hong Kong	Peritonitis	November 2005
NCT02872038	Chulalongkorn University\|The Kidney Foundation of Thailand\|Siam Pharmaceutical Co Ltd	Peritoneal Dialysis Associated Peritonitis	August 2015	Phase 4
NCT00609375	Javeriana University\|Asociacion Colombiana de Infectologia, ACIN. Infectious Diseases Society of Colombia\|Hospital Simon Bolivar, Bogota\|Clinica Palermo, Bogota\|Hospital Santa Clara, Bogota\|Fundación San Carlos, Bogota\|Hospital san Juan de Dios, Antioquia\|Hospital san Jorge, Pereira	Sepsis\|Bacteremia	September 2006	Phase 4
NCT04983901	M.D. Anderson Cancer Center\|Merck Sharp & Dohme LLC	Hematopoietic and Lymphoid Cell Neoplasm\|Malignant Solid Neoplasm	September 14, 2021	Phase 2
NCT03485950	M.D. Anderson Cancer Center\|Merck Sharp & Dohme LLC\|National Cancer Institute (NCI)	Other Infectious Diseases	May 16, 2018	Phase 2
NCT02732327	Forest Laboratories	Neoplasms\|Febrile Neutropenia	May 17, 2016	Phase 2
NCT03680612	Allecra\|Medpace, Inc.	Urinary Tract Infections	September 5, 2017	Phase 2
NCT01484015	Wake Forest University Health Sciences\|National Cancer Institute (NCI)	Adult Acute Lymphoblastic Leukemia\|Adult Acute Myeloid Leukemia\|Adult Burkitt Lymphoma\|Adult Diffuse Large Cell Lymphoma\|Adult Diffuse Mixed Cell Lymphoma\|Adult Diffuse Small Cleaved Cell Lymphoma\|Adult Hodgkin Lymphoma\|Adult Immunoblastic Large Cell Lymphoma\|Adult Lymphoblastic Lymphoma\|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative\|Breast Cancer\|Chronic Eosinophilic Leukemia\|Chronic Lymphocytic Leukemia\|Chronic Myelogenous Leukemia\|Chronic Myelomonocytic Leukemia\|Chronic Neutrophilic Leukemia\|Cutaneous T-cell Non-Hodgkin Lymphoma\|Disseminated Neuroblastoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Grade 1 Follicular Lymphoma\|Grade 2 Follicular Lymphoma\|Grade 3 Follicular Lymphoma\|Malignant Testicular Germ Cell Tumor\|Mantle Cell Lymphoma\|Marginal Zone Lymphoma\|Multiple Myeloma\|Mycosis Fungoides+Sezary Syndrome\|Myelodysplastic Syndromes\|Myelodysplastic+Myeloproliferative Neoplasms\|Neutropenia\|Nodal Marginal Zone B-cell Lymphoma\|Ovarian Epithelial Cancer\|Ovarian Germ Cell Tumor\|Plasma Cell Neoplasm\|Poor Prognosis Metastatic Gestational Trophoblastic Tumor\|Primary Myelofibrosis\|Prolymphocytic Leukemia\|Small Lymphocytic Lymphoma\|Splenic Marginal Zone Lymphoma	February 2011	Phase 1
NCT04009772	Assiut University\|Yasser Esmat Mohammed	Emergency Cesarean Section\|Infection Wound	July 1, 2019	Phase 2\|Phase 3
NCT00020865	Jonsson Comprehensive Cancer Center\|National Cancer Institute (NCI)	Fever, Sweats, and Hot Flashes\|Infection\|Leukemia\|Lymphoma\|Neutropenia\|Unspecified Adult Solid Tumor, Protocol Specific	September 2001	Phase 3
NCT04816968	Ospedale San Carlo Borromeo\|Associazione Oncologica Milanese AmoLaVita ONLUS	Severe Bacterial Infections	September 2021	Phase 1
NCT03870490	Venatorx Pharmaceuticals, Inc.\|National Institutes of Health (NIH)	Healthy Subjects	March 14, 2019	Phase 1
NCT03680378	Allecra	Healthy Subjects	July 1, 2017	Phase 1
NCT02302092	Takeda	Urinary Tract Infection	December 1, 2015	Phase 3

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 125 mg/mL ( 260.11 mM ; Need ultrasonic)

H ₂ O : 83.33 mg/mL ( 173.40 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.0809 mL	10.4045 mL	20.8091 mL
5 mM	0.4162 mL	2.0809 mL	4.1618 mL
10 mM	0.2081 mL	1.0405 mL	2.0809 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.08 mg/mL (4.33 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.08 mg/mL (4.33 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.08 mg/mL (4.33 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Yahav D, et al. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis. 2007 May;7(5):338-48.
[2] Barradell LB, Bryson HM. Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1994;47(3):471-505.
[3] Payne LE, et al. Cefepime-induced neurotoxicity: a systematic review. Crit Care. 2017 Nov 14;21(1):276. doi: 10.1186/s13054-017-1856-1.
[4] Máthé A, et al. The effect of different doses of cisplatin on the pharmacokinetic parameters of cefepime in mice. Lab Anim. 2006 Jul;40(3):296-300.

Synonyms

Pyrrolidinium, 1-[[(6R,7R)-7-[[(2Z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-methyl-, inner salt

Pyrrolidinium, 1-[[7-[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-methyl-, inner salt, [6R-[6α,7β(Z)]]-

Pyrrolidinium, 1-[[(6R,7R)-7-[[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-methyl-, inner salt

BMY 28142

Cefepime

FR 81335

Tsefepim

Cefimen K

Sefdin

Request a Quote

Please fill in your details below to request a COA for our product. We will send the COA to the provided email address promptly.

Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.

Information

Shipping
Privacy notice
Terms of Service
About us
Contact us

Customer service

Search
Custom Synthesis

My account

My account
Orders
Addresses
Shopping cart